Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
T-cell surface glycoprotein CD8 alpha chain（CD8A）
| Size | 100ug, 50ug |
|---|---|
| Brand | ProteoGenix |
| Product type | Recombinant Proteins |
| Host Species | Mammalian cells |
| Applications | Elisa, WB |
| Product name | T-cell surface glycoprotein CD8 alpha chain（CD8A） |
|---|---|
| Uniprot ID | P01732 |
| Origin species | Homo sapiens (Human) |
| Expression system | Eukaryotic expression |
| Sequence | MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDWSHPQFEKGGGSGGGSGGSSAWSHPQFEK |
| Protein delivered with Tag? | C-terminal Twin-Strep Tag |
| Purity estimated | >90%by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Delivery condition | Dry Ice |
| Delivery lead time in business days | Europe: 5-7 working days USA & Canada: 7-10 working days Rest of the world: 5-12 working days |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | ProteoGenix |
| Host species | Mammalian cells |
| Fragment Type | Met1-Asp182 |
| Aliases /Synonyms | T-lymphocyte differentiation antigen T8/Leu-2,CD8a,MAL |
| Reference | PX-P4639 |
| Note | For research use only |
Related products
Biosimilar
Crefmirlimab Biosimilar – Anti-CD8A mAb – Research Grade
PX-TA1828 238$
Biosimilar
Tifcemalimab Biosimilar – Anti-BTLA mAb – Research Grade
PX-TA1886 238$
Biosimilar
Hu23B12 Biosimilar – Anti-TSLP mAb – Research Grade
PX-TA1902 238$
Biosimilar
MOR014824 Biosimilar – Anti-TSLP mAb – Research Grade
PX-TA1905 238$
Biosimilar
Alglucosidase Alfa Biosimilar
PX-TA1910 238$
Biosimilar
CM101 Biosimilar – Anti-MPIF2 mAb – Research Grade
PX-TA1912 238$
Biosimilar
Zatuximab Biosimilar – Anti-HER1 mAb – Research Grade
PX-TA1921 238$
Ligand
Anoctamin-6(Ano6)
PX-P4625 250$Contact us
Send us a message from the form below
Reviews
There are no reviews yet.